Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-04-30T18:48:44.428Z Has data issue: false hasContentIssue false

Chapter 26 - Paragangliomas

Published online by Cambridge University Press:  19 October 2016

By
Markku Miettinen
Edited by
Markku Miettinen
Markku Miettinen
Affiliation:
National Cancer Institute, Maryland
Get access
Type
Chapter
Information
Modern Soft Tissue Pathology
Tumors and Non-Neoplastic Conditions
 , pp. 723 - 743
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Primary Sources

Lack, EE. Tumors of the Adrenal Glands and Extra-Adrenal Paraganglia, Fourth series, Fascicle 8. Washington, DC: Armed Forces Institute of Pathology, 2008.Google Scholar
Glenner, GG, Grimley, PM. Tumors of the Extra-Adrenal Paraganglion System (Including Chemoreceptors). Armed Forces Institute of Pathology Atlas of Tumor Pathology, Second series, Fascicle 9. Washington, DC: Armed Forces Institute of Pathology, 1974.Google Scholar

Secondary Sources

Gimenez-Roqueplo, AP, Dahia, PL, Robledo, M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012;44:328–333.Google ScholarPubMed
King, KS, Pacak, K. Familial pheochromocytomas and paragangliomas. Mol Cell Endocrinol 2014;386:92–100.CrossRefGoogle ScholarPubMed
Welander, J, Andreasson, A, Juhlin, CC, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2014;99:E1352–E1360.Google Scholar
Gill, AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 2012;44:285–292.CrossRefGoogle ScholarPubMed
Hoekstra, AS, Bayley, JP. The role of complex II in disease. Biochim Biophys Acta 2013;1827:543–551.CrossRefGoogle Scholar
Baysal, BE, Ferrell, RE, Willet-Brozick, JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848–851.Google Scholar
Niemann, S, Muller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 4. Nat Genet 2000;26:268–270.CrossRefGoogle Scholar
Astuti, D, Latif, F, Dallol, A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001;69:49–54.CrossRefGoogle ScholarPubMed
Burnichon, N, Brière, JJ, Libé, R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010;19:3011–3020.Google Scholar
Letouzé, E, Martinelli, C, Loriot, C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013;23:739–752.CrossRefGoogle ScholarPubMed
van Nederveen, FH, Gaal, J, Favier, J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764–771.CrossRefGoogle ScholarPubMed
Gill, AJ, Benn, DE, Chou, A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 2010;41:805–814.Google Scholar
Korpershoek, E, Favier, J, Gaal, J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011;96:E1472–E1476.CrossRefGoogle ScholarPubMed
Jochmanová, I, Zelinka, T, Widimský, J Jr, Pacak, K. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors. Physiol Res 2014;63(Suppl 2):S251–S262.Google Scholar
Cerecer-Gil, NY, Figuera, LE, Llamas, FJ, et al. Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma. Clin Cancer Res 2010;16:4148–4154.Google Scholar
Baysal, BE, McKay, SE, Kim, YJ, et al. Genomic imprinting at a boundary element flanking the SDHD locus. Hum Mol Genet 2011;20:4452–4461.Google Scholar
Kunst, HP, Rutten, MH, de Mönnink, JP, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res 2011;17(2):247–254.CrossRefGoogle ScholarPubMed
Mulligan, LM, Kwok, JB, Healey, CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458–460.Google Scholar
Hofstra, RM, Landsvater, RM, Ceccherini, I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375–376.CrossRefGoogle ScholarPubMed
Komminoth, P, Kunz, E, Hiort, O, et al. Detection of RET protooncogene point mutations in paraffin-embedded pheochromocytoma specimens in non-radioactive single-strand conformational polymorphism and direct sequencing. Am J Pathol 1994;145:922–929.Google Scholar
Eng, C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17:380–393.Google Scholar
Hes, F, Zewald, R, Peeters, T, et al. Genotype-phenotype correlations in families with deletions in the von Hippel–Lindau (VHL) gene. Hum Genet 2000;106:425–431.Google Scholar
Kaelin, WG. Von Hippel–Lindau disease. Annu Rev Pathol Mech Dis 2007;2:145–173.Google Scholar
Chou, A, Toon, C, Pickett, J, Gill, AJ. von Hippel–Lindau syndrome. Front Horm Res 2013;41:30–49.Google Scholar
Opocher, G, Conton, P, Sciavi, F, Macino, B, Mantero, F. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer 2005;4:13–16.Google Scholar
Bar, M, Friedman, E, Jakobovitz, O, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the von Hippel–Lindau and RET genes. Clin Endocrinol 1997;47:707–712.Google Scholar
Bausch, B, Borozdin, W, Mautner, VF, et al. Germline NF1 mutational spectra and loss of heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007;92:2784–2792.Google Scholar
Bausch, B, Borozdin, W, Neumann, HP, European-American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006;354:2729–2731.Google Scholar
Burnichon, N, Buffet, A, Parfait, B, et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 2012;21:5397–5405.Google Scholar
Ladroue, C, Carcenac, R, Leporrier, M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008;359(25):2685–2692.CrossRefGoogle ScholarPubMed
Yang, C, Zhuang, Z, Fliedner, SM, et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl) 2015;93:93–104.Google Scholar
Lorenzo, FR, Yang, C, Ng Tang Fui, M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 2013;91:507–512.Google Scholar
Qin, Y, Yao, L, King, EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010;42:229–233.Google Scholar
Yeh, IT, Lenci, RE, Qin, Y, et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 2008;124:279–285.Google Scholar
Comino-Méndez, I, Gracia-Aznárez, FJ, Schiavi, F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011;43:663–667.Google Scholar
Burnichon, N, Cascón, A, Schiavi, F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012;18:2828–2837.Google Scholar
Buffet, A, Venisse, A, Nau, V, et al. A decade (2001–2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 2012;44:359–366.Google ScholarPubMed
Tischler, AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 2008;132:1272–1284.CrossRefGoogle ScholarPubMed
Lendrers, JWM, Eisenhofer, G, Mannelli, M, Pacak, K. Phaeochromocytoma. Lancet 2005;366:665–675.CrossRefGoogle Scholar
Melicow, MM. One hundred cases of pheochromocytoma (107 tumors) at the Columbia-Presbyterian Medical Center, 1926–1976. Cancer 1977;40:1987–2004.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Medeiros, LJ, Wolf, BC, Balogh, K, Federman, M. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 1985;16:580–589.Google Scholar
Linnoila, RI, Keiser, HR, Steinberg, SM, Lack, EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 1990;21:1168–1180.Google Scholar
Webb, TA, Sheps, SG, Carney, JA. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neoplasia, type 2. Am J Surg Pathol 1980;4:121–126.Google Scholar
Koch, CA, Mauro, D, Walther, MM, et al. Pheochromocytoma in von Hippel–Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 2002;13:17–27.CrossRefGoogle ScholarPubMed
Thompson, LDR. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. Am J Surg Pathol 2002;26:551–566.Google Scholar
Hassoun, J, Monges, G, Giraud, B, et al. Immunohistochemical study of pheochromocytomas: an investigation of methionine-enkephalin, vasoactive intestinal polypeptide, somatostatin, corticotropin, β-endorphin, and calcitonin in 16 tumors. Am J Pathol 1984;114:56–63.Google Scholar
Hacker, GW, Bishop, AE, Terenghi, G, et al. Multiple peptide production and presence of general neuroendocrine markers detected in 12 cases of human phaeochromocytoma and in mammalian adrenal glands. Virchows Arch A Pathol Anat Histopathol 1988;412:399–411.Google Scholar
Linnoila, RI, Lack, EE, Steinberg, SM, Keiser, HR. Decreased expression of neuropeptides in malignant paragangliomas: an immunohistochemical study. Hum Pathol 1988;19:41–50.Google Scholar
Salmenkivi, K, Haglund, C, Arola, J, Heikkilä, P. Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 2001;25:1419–1423.Google Scholar
Lloyd, RV, Blaivas, M, Wilson, BS. Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. Arch Pathol Lab Med 1985;109:633–635.Google Scholar
Achilles, E, Padberg, BC, Holl, K, Klöppel, G, Schröder, S. Immunocytochemistry of paragangliomas: value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis. Histopathology 1991;18:453–458.Google Scholar
Nagura, S, Katoh, R, Kawaoi, A, et al. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol 1999;12:1107–1111.Google Scholar
Van Der Harst, E, Bruining, HA, Jaap Bonjer, H, et al. Proliferative index in pheochromocytomas: does it predict the occurrence of metastases? J Pathol 2000;191:175–180.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Brown, HM, Komorowski, RA, Wilson, SD, Demeure, MJ, Zhy, Y. Predicting metastases of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation. Cancer 1999;86:1583–1589.Google Scholar
Lack, EE, Cubilla, AL, Woodruff, JM, Lieberman, PH. Extra-adrenal paragangliomas of the retroperitoneum: a clinicopathologic study of 12 tumors. Am J Surg Pathol 1980;4:109–120.CrossRefGoogle ScholarPubMed
Moran, CA, Albores-Saavedra, J, Wenig, BM, Mena, H. Pigmented extraadrenal paragangliomas: a clinicopathologic and immunohistochemical study of five cases. Cancer 1997;79:398–402.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Honma, K. Paraganglia of the urinary bladder: an autopsy study. Zentralbl Pathol 1994;139:465–469.Google ScholarPubMed
Leestma, JE, Price, EB. Paraganglioma of the urinary bladder. Cancer 1971;28:1063–1073.Google Scholar
Grignon, DJ, Ro, JY, Mackay, B, et al. Paraganglioma of the urinary bladder: immunohistochemical, ultrastructural, and DNA flow cytometric studies. Hum Pathol 1991;22:1162–1169.Google Scholar
Cheng, L, Leibovich, BC, Cheville, JC, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer 2000;88:844–852.Google Scholar
Mason, EF, Sadow, PM, Wagner, AJ, et al. Identification of succinate dehydrogenase-deficient bladder paragangliomas. Am J Surg Pathol 2013;37:1612–1618.Google Scholar
Olson, JL, Salyer, WR. Mediastinal paragangliomas (aortic body tumor): a report of four cases and a review of literature. Cancer 1978;41P:2405–2412.Google Scholar
Lack, EE, Stillinger, RA, Colvin, DB, Groves, RM, Burnette, DG. Aorticopulmonary paraganglioma: report of a case with ultrastructural study and review of the literature. Cancer 1979;43:269–278.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
Johnson, TL, Lloyd, RV, Shapiro, B, et al. Cardiac paragangliomas: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 1985;9:827–833.CrossRefGoogle ScholarPubMed
Gallivan, MVE, Chun, B, Rowden, G, Lack, EE. Intrathoracic paravertebral paraganglioma. Arch Pathol Lab Med 1980;104:46–51.Google ScholarPubMed
Moran, CA, Suster, S, Fishback, N, Koss, MN. Mediastinal paragangliomas: a clinicopathologic and immunohistochemical study of 16 cases. Cancer 1993;72:2358–2364.Google Scholar
Else, T, Marvin, ML, Everett, JN, et al. The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3). J Clin Endocrinol Metab 2014;99:E1482–E1486.CrossRefGoogle ScholarPubMed
Saldana, MJ, Salem, LE, Travezan, R. High altitude hypoxia and chemodectomas. Hum Pathol 1973;4:251–263.CrossRefGoogle ScholarPubMed
Arias-Stella, J, Valcarcel, J. Chief cell hyperplasia in the human carotid body at high altitudes: physiologic and pathologic significance. Hum Pathol 1976;7:361–373.Google Scholar
Rodriguez-Cuevas, S, Lopez-Garza, J, Labastida-Almendaro, S. Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck 1998;20:374–378.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Jansen, JC, Van Den Berg, R, Kuiper, A, et al. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 2000;88:2811–2816.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
Shamblin, WR, ReMine, WH, Sheps, SG, Harrison, EG. Carotid body tumor (chemodectoma): clinicopathologic analysis of 90 cases. Am J Surg 1971;122:732–739.Google Scholar
Lack, EE, Cubilla, AL, Woodruff, JM. Paragangliomas of the head and neck region: a pathologic study of tumors from 71 patients. Hum Pathol 1979;10:191–218.CrossRefGoogle ScholarPubMed
Hodge, KM, Byers, RM, Peters, LJ. Paragangliomas of the head and neck. Arch Otolaryngol Head Neck Surg 1988;114:872–877.Google Scholar
Nora, JD, Hallett, JW Jr, O’Brien, PC, et al. Surgical resection of carotid body tumors: long-term survival, recurrence and metastasis. Mayo Clin Proc 1988;63:348–352.Google Scholar
Lee, JH, Barich, F, Karnell, LH, et al. National cancer database report on malignant paragangliomas of the head and neck. Cancer 2002;94:730–737.Google Scholar
Netterville, JL, Jackson, CG, Miller, FR, Wanamaker, JR, Glasscock, ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg 1998;124:1133–1140.Google Scholar
Miller, RB, Boon, MS, Atkins, JP, Lowry, LD. Vagal paraganglioma: the Jefferson experience. Otolaryngol Head Neck Surg 2000;122:482–487.Google Scholar
Heinrich, MC, Harris, AE, Bell, WR. Metastatic intravagal paraganglioma: case report and review of the literature. Am J Med 1985;78:1017–1024.CrossRefGoogle ScholarPubMed
Tannir, NM, Cortas, N, Allam, C. A functioning catecholamine-secreting vagal body tumor: a case report and review of literature. Cancer 1983;52:932–935.Google Scholar
Plaza, JA, Wakely, PE, Moran, C, Fletcher, CDM, Suster, S. Sclerosing paraganglioma: report of 19 cases of an unusual variant of neuroendocrine tumor that may be mistaken for an aggressive malignant neoplasm. Am J Surg Pathol 2006;30:7–12.Google Scholar
Hamid, Q, Varndell, IM, Ibrahim, NB, Mingazzini, P, Polak, JM. Extraadrenal paragangliomas: an immunocytochemical and ultrastructural report. Cancer 1987;60:1776–1781.Google Scholar
Kliewer, KE, Wen, DR, Cancilla, PA, Cochran, AJ. Paragangliomas: assessment of prognosis by histologic, immunohistochemical, and ultrastructural techniques. Hum Pathol 1989;20:29–39.Google Scholar
Brown, JS. Glomus jugulare tumors revisited: a ten-year statistical follow-up of 231 cases. Laryngoscope 1985;95:284–288.CrossRefGoogle ScholarPubMed
Van Der Mey, AG, Frijns, JH, Cornelisse, CJ, et al. Does intervention improve the natural course of glomus tumors?: a series of 108 patients seen in a 32-year period. Ann Otol Rhinol Laryngol 1992;101:635–642.Google Scholar
Lim, M, Bower, R, Nangiana, JS, Adler, JR, Chang, SD. Radiosurgery for glomus jugulare tumors. Technol Cancer Res Treat 2007;6:419–423.Google Scholar
Kepes, JJ, Zacharias, DL. Gangliocytic paraganglioma of the duodenum: a report of two cases with light and electron microscopic examination. Cancer 1971;27:61–70.Google Scholar
Reed, RJ, Daroca, PJ Jr, Harkin, JC. Gangliocytic paraganglioma. Am J Surg Pathol 1977;1:207–216.Google Scholar
Perrone, T, Sibley, RK, Rosai, J. Duodenal gangliocytic paraganglioma: an immunohistochemical and ultrastructural study and hypothesis concerning its origin. Am J Surg Pathol 1985;7:31–41.Google Scholar
Scheithauer, BW, Nora, FE, Lechago, J, et al. Duodenal gangliocytic paraganglioma: clinicopathologic and immunohistochemical study of 11 cases. Am J Clin Pathol 1986;86:559–565.Google Scholar
Burke, AP, Helwig, EB. Gangliocytic paraganglioma. Am J Clin Pathol 1989;92:1–9.Google Scholar
Inai, K, Kobuke, T, Yonehara, S, Tokuoka, S. Duodenal gangliocytic paraganglioma with lymph node metastasis in a 17-year-old boy. Cancer 1989;63:2540–2545.3.0.CO;2-H>CrossRefGoogle Scholar
Dookhan, DB, Miettinen, M, Finkel, G, Gibas, Z. Recurrent duodenal gangliocytic paraganglioma with lymph node metastases. Histopathology 1993;22:399–401.CrossRefGoogle ScholarPubMed
Hamid, QA, Bishop, AE, Rode, J, et al. Duodenal gangliocytic paragangliomas: a study of 10 cases with immunocytochemical neuroendocrine markers. Hum Pathol 1986;17:1151–1157.Google Scholar
Sonneland, PRL, Scheithauer, BW, Lechago, J, Crawford, BG, Onofrio, BM. Paraganglioma of the cauda equina region: clinicopathologic study of 31 cases with special reference to immunocytology and ultrastructure. Cancer 1986;58:1720–1735.Google Scholar
Moran, CA, Rush, W, Mena, H. Primary spinal paragangliomas: a clinicopathological and immunohistochemical study of 30 cases. Histopathology 1997;31:167–171.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×